297 related articles for article (PubMed ID: 37289203)
1. Dendritic cell vaccine trials in gliomas: Untangling the lines.
Hotchkiss KM; Batich KA; Mohan A; Rahman R; Piantadosi S; Khasraw M
Neuro Oncol; 2023 Oct; 25(10):1752-1762. PubMed ID: 37289203
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures.
Li L; Zhou J; Dong X; Liao Q; Zhou D; Zhou Y
Int Immunopharmacol; 2022 Aug; 109():108929. PubMed ID: 35700581
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions.
Zhou J; Li L; Jia M; Liao Q; Peng G; Luo G; Zhou Y
Cancer Med; 2023 Mar; 12(6):7207-7221. PubMed ID: 36464889
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell vaccine of gliomas: challenges from bench to bed.
Zheng Y; Ma X; Feng S; Zhu H; Chen X; Yu X; Shu K; Zhang S
Front Immunol; 2023; 14():1259562. PubMed ID: 37781367
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell immunotherapy for malignant gliomas.
Luptrawan A; Liu G; Yu JS
Rev Recent Clin Trials; 2008 Jan; 3(1):10-21. PubMed ID: 18474011
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell based vaccination strategy: an evolving paradigm.
Filley AC; Dey M
J Neurooncol; 2017 Jun; 133(2):223-235. PubMed ID: 28434112
[TBL] [Abstract][Full Text] [Related]
7. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma.
Jie X; Hua L; Jiang W; Feng F; Feng G; Hua Z
Cell Biochem Biophys; 2012 Jan; 62(1):91-9. PubMed ID: 21909820
[TBL] [Abstract][Full Text] [Related]
8. Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.
Batich KA; Mitchell DA; Healy P; Herndon JE; Sampson JH
Clin Cancer Res; 2020 Oct; 26(20):5297-5303. PubMed ID: 32719000
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
10. Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
Schaller TH; Sampson JH
Expert Rev Vaccines; 2017 Jan; 16(1):27-36. PubMed ID: 27500911
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
12. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
Batich KA; Swartz AM; Sampson JH
Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
14. Tumor Vaccines for Malignant Gliomas.
Srinivasan VM; Ferguson SD; Lee S; Weathers SP; Kerrigan BCP; Heimberger AB
Neurotherapeutics; 2017 Apr; 14(2):345-357. PubMed ID: 28389997
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.
Garg AD; Vandenberk L; Koks C; Verschuere T; Boon L; Van Gool SW; Agostinis P
Sci Transl Med; 2016 Mar; 8(328):328ra27. PubMed ID: 26936504
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials.
Lv L; Huang J; Xi H; Zhou X
Int Immunopharmacol; 2020 Jun; 83():106336. PubMed ID: 32213460
[TBL] [Abstract][Full Text] [Related]
18. Vaccination in the immunotherapy of glioblastoma.
Kong Z; Wang Y; Ma W
Hum Vaccin Immunother; 2018 Feb; 14(2):255-268. PubMed ID: 29087782
[TBL] [Abstract][Full Text] [Related]
19. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.
Pellegatta S; Poliani PL; Corno D; Grisoli M; Cusimano M; Ubiali F; Baggi F; Bruzzone MG; Finocchiaro G
Neurol Res; 2006 Jul; 28(5):527-31. PubMed ID: 16808884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
